This product can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects

This product can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects.

This product can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects.

This product can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects.

This product can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects.

This product can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects.

This product can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects.

This product can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects.

This product can inhibit the synthesis of prostaglandins and has antipyretic and analgesic effects.

This product is a competitive angiotensin converting enzyme inhibitor, which prevents angiotensin I from being converted into angiotensin II, thereby reducing peripheral vascular resistance and reducing water and sodium retention by inhibiting aldosterone secretion. This product can also dilate peripheral blood vessels by interfering with the degradation of bradykinin. For patients with heart failure, this product can also reduce capillary wedge pressure and pulmonary vascular resistance, increase cardiac output and exercise tolerance time.

By blocking the membrane transport of calcium ions in myocardial and vascular smooth muscle, inhibiting the influx of calcium ions into cells, it causes a decrease in myocardial contractility and vasodilation. Animal experiments have shown that by reducing myocardial contractility and peripheral vascular resistance, myocardial oxygen consumption is reduced; by dilating coronary vessels and developing collateral circulation, the oxygen supply to myocardial ischemic sites is increased; by inhibiting the consumption of high-energy phosphate compounds, the ability to resist hypoxia is enhanced.

This product is an intermediate in the synthesis of Schisandrae Chinensis A, which can reduce liver damage and alanine aminotransferase (ALT) elevation caused by carbon tetrachloride; inhibit liver microsomal lipid peroxidation and metabolic conversion to carbon monoxide caused by carbon tetrachloride, and reduce the consumption of reduced coenzyme II and oxygen in the metabolic process, protect the structure and function of liver cell biomembrane; reduce the increase of liver ALT induced by prednisone, and promote liver regeneration in mice with partial hepatectomy; have a significant induction effect on cytochrome P450 enzyme activity, enhance the detoxification ability of carbon tetrachloride and certain carcinogens; improve protein metabolism in some hepatitis patients, increase albumin and reduce globulin. It has no negative conversion effect on HbsAg and HbeAg, and cannot shrink enlarged liver and spleen.